OptiNose (OPTN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
August 11, 2022 7:00 AM EDTCompany reports second quarter XHANCE net revenue of $20.6 million increased 12%
compared to second quarter 2021
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022
Company expects full year 2022 XHANCE net revenue to be between $85 to $92 million
Company expects full year 2022 and operating expenses to be between $129 to $134 million
Conference call and webcast to be held today at 8:00 a.m. Eastern Time
YARDLEY, Pa., Aug.... More
